Validation of a Coating System for Implants and Endoprostheses with Activatable Properties
More than 400,000 joint replacements are performed in Germany each year. Implant-associated infections occur in up to 2 % of all procedures. In revision surgeries, this risk rises up to 40 %. The consequences are serious: prolonged hospital stays, loss of function, and, in the worst cases, amputation or sepsis. Existing coating solutions are usually only effective for a short time and offer no protection against late-onset infections.
The Clinic for General Orthopedics and Tumor Orthopedics at the University Hospital Münster is developing a novel dual-layer coating system for titanium implants. A resorbable triglyceride layer releases vancomycin over a period of six weeks, thereby preventing early-onset infections. An underlying poly-L-lactide layer containing silver ions can be noninvasively activated in a targeted manner using extracorporeal shock waves in the event of late-onset infections.
With this funding, the system will undergo preclinical validation: manufacturing processes will be optimized, biological safety in accordance with ISO 10993 will be demonstrated, and long-term stability will be verified as the basis for technology transfer toward clinical approval.
Click here for the website of the Else Kröner Fresenius Foundation
Click here for the LinkedIn post
